FOR BIOTECH INNOVATORS
Your clinical program isn’t over. It’s underfunded.
A failed Phase 3 does not always mean a failed drug. The same applies to late-stage clinical programs stalled by funding gaps, incomplete pivotal trials, regulatory setbacks, or promising signals that require a targeted confirmatory path.
If your asset has compelling clinical data in a defined sub-population, a viable regulatory pathway, or a clear opportunity to generate additional evidence — but not the capital to get there — AllianceXPartners can help.
AllianceXPartners can co-fund and coordinate the confirmatory clinical program through its network of regional partners, complementing the sponsor’s existing U.S. trial activities. No cash contribution from you. No priced equity round. No restarting from zero.
Just a structured path to the next clinical inflection point — and ultimately, the filing.
What you keep
- US and rest-of-world commercial rights
- Control of your own regulatory strategy and FDA relationship
- Your cap table — no priced equity round required
- Full ownership of the underlying IP
What you get
- A fully completed confirmatory trial without requiring additional sponsor cash
- An FDA-usable, inspection-ready data package built to support regulatory review
- A compliant, two-track clinical site network that advances U.S. and regional execution in parallel
- An EAEU commercial partner already lined up to support commercialization across the region
Do you fit the profile?
AllianceXPartners looks for late-stage clinical programs with a credible path to a value inflection point. That can include a Phase 3 or other pivotal trial that missed its primary endpoint in the overall population but identified a pre-specified or post-hoc sub-population with a statistically credible, clinically meaningful effect; a late Phase 2/2b program with compelling efficacy and a clear path into a pivotal study; or another late-stage program where the clinical and regulatory path has become defined but funding has run out.
The common thread is a de-risked clinical asset, a defensible path to the next meaningful trial or regulatory milestone, and insufficient capital to get there. Explicit FDA feedback is ideal, but a well-supported regulatory strategy and a credible path to FDA alignment can also qualify.
If that describes your program, the missing piece usually isn’t the science. It’s the capital required to reach the next inflection point.
What we ask in return
A low-to-mid single-digit royalty on worldwide net sales, a small warrant struck near today’s price, and exclusive EAEU commercial rights sublicensed through AXP to our regional partner. That’s it — no cash, no board seat, no operational control. The royalty and warrant are sized so the combined burden never threatens your next financing round or discourages a future acquirer; see How It Works for the full structure.
AllianceXPartners 